Navigation Links
Gregory J. Tibbitts Appointed Chief Financial Officer at Accumetrics, Inc.
Date:2/26/2009

SAN DIEGO, Calif., Feb. 26 /PRNewswire/ -- Accumetrics, Inc. announced today that the Company has appointed Gregory J. Tibbitts, CPA to the position of Chief Financial Officer.

"We believe Greg's extensive experience in both private and public companies will help Accumetrics to advance our financial operations and bring continued success to the Company," says Timothy I. Still, Chief Executive Officer at Accumetrics. "His deep knowledge of the capital markets and the medical device arena will be important as we maximize the commercial opportunity for our technology."

Mr. Tibbitts's background includes 19 years of corporate finance and technical accounting experience balanced between public accounting and private industry. He has held positions with both publicly traded and privately-held companies, with expertise in risk management, treasury, financing and financial operations.

Prior to Accumetrics, Mr. Tibbitts served as Chief Financial Officer of CryoCor, a publicly-traded medical device company, prior to its acquisition by Boston Scientific Corporation. Mr. Tibbitts joined CryoCor in mid-2004, and was heavily involved in both its Initial Public Offering in July 2005 and its ultimate acquisition in 2008 by Boston Scientific. Before joining CryoCor, Mr. Tibbitts served as Chief Financial Officer of Elitra Pharmaceuticals, a privately-held biotechnology company, and as a Senior Manager in the audit practice of Ernst & Young LLP.

Mr. Tibbitts received a BBA degree from the University of San Diego, and an MBA from San Diego State University, and serves on the Board of Directors of IDMI Pharmaceuticals, a publicly-traded biotechnology company.

About Accumetrics (www.accumetrics.com)

Accumetrics is committed to advancing medical understanding of platelet response and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy to use platform for measuring an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix(R), ReoPro(R), and Integrilin(R), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis.

    CONTACT:    Jules Abraham
                Lippert Heilshorn & Associates
                212-838-3777
                jabraham@lhai.com

                Timothy I. Still
                Accumetrics
                press@accumetrics.com


'/>"/>
SOURCE Accumetrics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dr. Gregory Sawyer, of Los Gatos, Has Been Selected by the American Dental Association for the Evidence-Based Dentistry Champion Conference
2. MDdatacor Names Gregory Buchholz Chief Operating Officer
3. American Hospital Management Company Appoints Gregory Ciottone, MD as Chief Medical Officer
4. Congressman Gregory W. Meeks to Ask for Suspension of CARES Process at the St. Albans Veteran Campus
5. Synthetech Announces Appointment of Dr. Gregory R. Hahn as President and Chief Executive Officer
6. Gregory A. Adams Named Northern California Region President of Kaiser Foundation Health Plan and Hospitals
7. Dr. Gregory Buford and Top Plastic Surgeon Selected as a Keynote Speaker at Spa & Resort Expo LA Convention Center, February 23-25
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brickson Diamond Appointed Board Chair of National Hospice Foundation
10. Valensa Internationals Dr. Rudi E. Moerck Appointed CEO
11. Margaret Laub Appointed to IntelliDOT Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... compare student test score performance for the 2015-16 school year across Wisconsin’s public ... programs. Though it highlights important patterns in student test score performance, the report’s ...
(Date:4/25/2017)... ... 25, 2017 , ... As pharmaceutical companies are held to ... process innovation in drug formulation and manufacturing. CoreRx offers its clients more ... in support of their development and manufacturing goals. , The company was ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the ... or chronic problems, I focus on preventative care with all my patients to alleviate possible ... questions, always feel free to contact my office and my trained staff will assist you ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , a ... UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event ... the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
Breaking Medicine Technology: